CDK6 and acute myeloid leukemia: In this study, we investigated the efficacies and molecular effects of CDK6 and GSPT1 degraders in two pediatric AML subtypes expressing either RUNX1::RUNX1T1, the most common fusion gene in pediatric AML, or FUS::ERG, which is associated with a very poor prognosis [14,19].